Clinical trial
Fulvestrant in Treating Patients With Recurrent Prostate Cancer
NCT00217464 · Roswell Park Cancer Institute, Other · Terminated
Key facts
| NCT number | NCT00217464 |
|---|---|
| Title | Fulvestrant in Treating Patients With Recurrent Prostate Cancer |
| Official title | Multicenter Study of Fulvestrant (Faslodex®) in Early, Recurrent Prostate Cancer Following Local Therapy: A Phase II Trial |
| Lead sponsor | Roswell Park Cancer Institute, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | fulvestrant |
| Enrollment | 17 |
| Start date | Jun 1, 2004 |
| Primary completion | Feb 1, 2010 |
| Completion | Mar 1, 2010 |
| First posted | Sep 22, 2005 |
| Last update posted | Apr 16, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: